Neurocrine Biosciences (NBIX) Q3 2026 earnings review
Neurocrine drug sales pass $1 billion, and its outlook rises
Neurocrine Biosciences, a maker of medicines for movement and hormone disorders, topped $1 billion in quarterly drug sales as its two newer treatments joined its main product. Sales from businesses owned a year ago grew 28% by our math, and total revenue rose 41% to $1.1 billion with the newly acquired Vykat XR. Chief executive Kyle Gano raised the full-year Ingrezza sales outlook and cut the overhead cost plan, though by our math the new target implies Ingrezza growth slowing to about 12% in the fourth quarter.
| Sales from businesses owned a year ago | +28% total revenue $1,123M (+41%) |
|---|---|
| Ingrezza net product sales | $801M +17% from a year ago |
| Profit per share, excluding one-offs | $3.29 +52% from a year ago (GAAP $1.96, -4%) |
| Full-year Ingrezza sales outlook | Raised $62.5M middle of the range: $2.91B (+16%) |
⚖️ Verdict: 🟢 Bullish
The story got better because all three commercial medicines beat the pace implied by the company's prior plan. Vykat XR reached $107 million in its first full quarter instead of staying flat near $94 million as management had cautioned, and Crenessity climbed to $211 million. One caution: the company still gives no full-year sales plan or patient counts for either newer medicine, and ongoing patent write-downs plus a stock-portfolio loss pushed reported net income down 1%.
The question now is whether Vykat XR and Crenessity can keep adding patients at this pace or if early demand is leveling off inside small rare-disease pools. If early Vykat XR patient drop-offs are truly behind it and Crenessity keeps expanding past its initial patient base, both drugs will keep growing sequentially; if not, growth will flatten once the first wave of patients is treated. Fourth-quarter sales for both medicines and 2027 outlook commentary will tell.
🐂 Bull Case
Ingrezza Beat Tough Comparisons and Raised Its Plan
Ingrezza, Neurocrine's flagship medicine for involuntary movement disorders, had a high bar to clear because last year's third quarter included an extra ordering week. Even so, sales reached $801 million, up 17% from a year ago and 12% from the second quarter. The drugmaker cited "double-digit volume growth, with record TRx and NRx supported by strong demand and high rates of persistency", meaning both total and new prescriptions hit highs.
Because third-quarter demand outran the old plan, management raised its full-year Ingrezza outlook by $62.5 million at the middle of the range, to $2.90–2.925 billion. By our math, that leaves $739 million for the fourth quarter, or 12.3% growth from a year ago. A newly published study also showed the medicine helped patients with mild symptoms, which supports prescribing to a broader group.
What to watch: fourth-quarter Ingrezza sales against the $726–751 million range implied by the full-year outlook. A finish above the top end would show that prescription growth is still outrunning contracted price discounts heading into 2027.
Two Newer Rare-Disease Drugs Reached $318 Million
Chief executive Kyle Gano highlighted "net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines." For years the San Diego biotech relied almost entirely on Ingrezza, so it launched Crenessity, a treatment for a rare adrenal gland disorder, and bought Soleno Therapeutics in May 2026 to add Vykat XR, a medicine for extreme hunger in Prader-Willi syndrome.
- Crenessity sales: $211 million, up 14.7% from the second quarter and 115.3% from a year ago
- Vykat XR sales: $107 million in its first full quarter, up 13.8% from $94 million on a full-quarter basis in the second quarter, by our math
- Share of product sales: 28.4% from the two newer medicines, up from 12.4% a year ago, by our math
Both medicines cleared key tests this quarter. Crenessity added $27 million over the prior quarter with "steady new patient demand and high rates of persistency with approximately 80% reimbursement for dispensed prescriptions". Vykat XR grew instead of staying flat as management had cautioned last quarter, supported by "steady and consistent patient demand and persistency". One quarter does not settle whether early Vykat XR patient drop-offs are over, but the early growth reduces the risk that the $2.9 billion purchase has stalled.
What to watch: fourth-quarter Vykat XR sales compared with this quarter's $107 million. Another sequential gain would confirm that new patient starts are outpacing patients who stop taking the drug.
Overhead Costs Fell as a Share of Sales
Neurocrine expanded its sales force in the first quarter and absorbed Soleno's commercial team in May, yet selling and overhead expenses grew much slower than revenue. Excluding one-offs, selling, general and administrative costs rose 25.9% from a year ago to $326.6 million, while total revenue rose 41.2%. By our math, that lowered overhead costs by 3.5 percentage points of revenue, to 29.1%, and the company cut its full-year overhead outlook by $37.5 million at the middle of the range.
What to watch: fourth-quarter selling and overhead costs, excluding one-offs, against the $387 million implied by the full-year outlook. Spending at that level would be a $61 million jump from the third quarter, showing whether the savings are lasting or just delayed bills.
🐻 Bear Case
Reported Profit Fell as Deal and Stock Costs Hit
Gano said the quarter's revenue growth "expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company." Yet while profit per share excluding one-offs rose 51.6% to $3.29, reported net income slipped 1.4% from a year ago to $206.5 million, and reported profit per share fell 3.9% to $1.96. The gap between the two profit measures stays wide because non-GAAP profit strips out real costs from the Soleno purchase and investment swings.
- Amortization of acquired intangible assets: $35.0 million, up 3.0 percentage points of revenue from a year ago, by our math
- Employee severance and acquisition pay: $16.7 million, plus $6.3 million of acquired inventory write-ups
- Paper loss on equity investments: $52.3 million, compared with a $30.6 million gain a year ago
- Research and development: $351.8 million on a reported basis, up 40.7% from a year ago
The stock-portfolio loss will fluctuate, and by our math pre-tax profit excluding those equity swings grew 28.6% from a year ago. However, the $2.2 billion of Vykat XR patent rights will cost about $35 million a quarter to write down for 16 years, and $168 million of stepped-up inventory will run through cost of sales over several years. Because Neurocrine paid $2.9 billion in cash to acquire those assets, the write-downs represent the ongoing bill for the revenue Vykat XR brings in.
What to watch: acquisition-related employee and integration charges in the fourth quarter. Those cash charges totaled $18.6 million this quarter and should shrink if the Soleno integration is finishing.
No Sales Plan or Patient Counts for Newer Drugs
Crenessity and Vykat XR generated $318 million this quarter, or 28.3% of total revenue by our math, yet Neurocrine still provides no full-year sales outlook for either medicine. In addition, the release gave no patient counts for Crenessity: throughout 2025 the company published quarterly new-patient enrollment forms, and last quarter it gave the share of the roughly 20,000 US patients who had been prescribed the drug. Neither figure appeared in the third-quarter release, leaving investors with no way to see whether new patient additions are slowing as the easiest-to-reach patients get treated.
What to watch: the quarterly filing and 2027 outlook commentary for either an active-patient count on Crenessity or a formal 2027 sales target for the two newer drugs. Continued silence would mean nearly a third of revenue remains without a testable company target.
Risks this quarter didn't answer
Five standing legal, regulatory and clinical risks received no new numbers or updates in the third-quarter earnings release.
- Department of Justice investigation into Ingrezza sales and marketing: disclosed in August 2025; the quarterly filing's legal note will show whether the scope or timeline has changed.
- Medicare price negotiations on Ingrezza for 2029: discussions begin in 2027; management's 2027 outlook commentary will show the price cost of keeping 70% Medicare coverage.
- Late-stage trial readouts for osavampator in depression and direclidine in schizophrenia: both remain slated for 2027, when topline trial results will settle whether the $1.3 billion research budget pays off.
- Generic patent challenge by Zydus against Ingrezza Sprinkle and Soleno shareholder litigation: both await court rulings and legal-note updates in the quarterly filing.
- New rival in congenital adrenal hyperplasia: a competing drug candidate was recently bought by a larger rival; Crenessity's sequential sales pace will show whether doctors wait or switch.
👓 Other Themes
CMO Return and Early Obesity and Alzheimer's Trials
Former chief medical officer Eiry Roberts rejoined the executive team in her old role ahead of a December 15 research day. Meanwhile, the biotech began a first human trial of NBIP-'1968, a triple-hormone drug for obesity that will join an earlier study to "inform the development of a novel co-formulated combination therapy", and started a mid-stage trial of NBI-'567 for memory loss in Alzheimer's disease.
💲 Other KPIs
Cash and investments rebounded by $308.0 million from the second quarter, by our math, after falling from $2.54 billion at year-end to $481.7 million in June when Neurocrine paid for Soleno. Strong third-quarter product sales rebuilt the cash cushion without drawing on the credit line.
Uncollected bills from drug wholesalers rose 39.4% from $686.8 million at the end of 2025, by our math. That matches the 40.9% rise in nine-month revenue, showing that adding Vykat XR and growing Crenessity have not slowed customer payments.
The diluted share count rose 2.6% from 102.5 million a year ago, continuing a steady climb from 103.4 million in the first quarter and 104.2 million in the second. Because the biotech put its cash into buying Soleno instead of buying back stock, employee stock grants are now nudging the share count up.
🔮 Guidance
Raised. The middle of the range moved up $62.5 million to $2,912.5 million, or 15.9% growth for the year by our math. By our math, that leaves $738.6 million for the fourth quarter, or 12.3% growth from a year ago against this quarter's 16.6%. It is the second raise this year: held in Q1, +$100M in Q2, and +$62.5M in Q3.
Unchanged. The plan keeps reported research spending at $1.30 billion at the middle of the range, up 28.0% for the year by our math. That leaves $325.3 million for the fourth quarter, down from $351.8 million in the third quarter and up 26.0% from a year ago, as late-stage depression and schizophrenia trials continue.
Unchanged. Excluding $115 million of stock pay and deal costs, research spending stays at $1,165 million at the middle of the range, up 26.0% for the year by our math. That implies $299.9 million in the fourth quarter, down from $317.0 million this quarter and up 28.3% from a year ago.
Raised. Upfront spending on licensed research programmes moved up $11 million to match the $34.4 million already spent in the first nine months, including $11.7 million this quarter. Because the company only budgets for deals already signed, the plan implies zero in the fourth quarter unless new licensing deals close.
Cut. The middle of the reported overhead range came down by $37.5 million to $1,550 million, or 34.1% growth for the year by our math, after previously rising by $200 million in the second quarter for the Soleno purchase. By our math, that leaves $425.5 million for the fourth quarter, up 41.0% from a year ago and up from $366.3 million in the third quarter.
Cut. Excluding $170 million of stock pay and $95 million of deal costs, the overhead plan dropped $37.5 million at the middle of the range to $1,300 million, or 26.8% full-year growth by our math. That leaves $387.3 million for the fourth quarter, up 45.8% from a year ago and above this quarter's $326.6 million.
Unchanged. The write-down of Vykat XR patent rights stays at $87.5 million at the middle of the range. With $51.5 million recorded through September, the plan leaves $36.0 million for the fourth quarter by our math, matching this quarter's $35.0 million pace.
❓ Key Questions
How many patients are actively taking Crenessity today?
The release gave neither quarterly new-patient enrollment forms nor an updated percentage of the 20,000 US patient pool prescribed the drug. Without an active-patient or new-start count, investors cannot tell how much of the $211 million quarter came from new patients versus refills.
Have early Vykat XR patient drop-offs finished?
Last quarter management expected third-quarter Vykat XR sales to stay flat near $94 million while early patients stopped treatment, yet sales reached $107 million. Did drop-offs clear faster than planned, or did timing of distributor orders boost the quarter?
Why does the overhead plan imply a fourth-quarter jump?
Even after the $37.5 million cut, the full-year outlook excluding one-offs implies $387 million of fourth-quarter selling and overhead costs by our math, up $61 million from the third quarter. What new commercial spending drives that step-up?
What is the status of the Justice Department Ingrezza inquiry?
Neurocrine received a civil investigative demand regarding Ingrezza sales and marketing in August 2025 and has not discussed it on recent calls. Any update on timing or potential cost matters because Ingrezza still supplies 71% of revenue.